Conference Coverage
Conference Coverage
Docetaxel Bests Erlotinib in EGFR Wild-Type Lung Cancer
Major Finding: Medium progression-free survival was 3.4 months with docetaxel vs.
Conference Coverage
Selumetinib Cracks Door to Targeted Therapy for KRAS-Mutant NSCLC
Major Finding: The primary end point of overall survival was 5.2 months with docetaxel plus placebo and 9.4 months with docetaxel and selumetinib...
Conference Coverage
AACE: Does Diabetes Raise the Risk of Cancer?
Conference Coverage
Pemetrexed Maintenance Extends Survival of Advanced Lung Cancer
Major Finding: Median overall survival from randomization was 13.9 months with pemetrexed maintenance plus best supportive care vs.
Conference Coverage
Paclitaxel Matches New Drugs as First-Line Breast Cancer Therapy
Major Finding: With a median follow-up of 12 months, progression-free survival was 10.6 months with paclitaxel, which was comparable to nab-...
Conference Coverage
Stanford Experience Shows Long Metastatic BCC Survival
Major Finding: The median overall survival from the time of diagnosis of metastatic basal cell carcinoma was 7.8 years in a single-center series,...
Conference Coverage
Hodgkin's Survivors Face High Breast Cancer Risk
Major Finding: Nearly a third (30%) of females treated with chest radiation for Hodgkin’s lymphoma was diagnosed with breast cancer by age 50.Data...
Conference Coverage
FDA: Drug Shortages Decline but Persist
Conference Coverage
Two Targeted Agents Best Chemotherapy in BRAF-Mutant Melanoma
Major Finding: Relative to chemotherapy, trametinib improved progression-free survival (hazard ratio, 0.45) and overall survival (HR, 0.54), and...